ARS Pharmaceuticals, Inc.

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
9.060 ^USD	-0.66%		-2.37%	-22.23%

Feb. 10	Ars Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on Neffy®? (Epinephrine Nasal Spray) At 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting	CI
Feb. 02	ARS Pharmaceuticals Announces EURneffy 1 Mg (Adrenaline Nasal Spray) Recommended For Approval In The EU For Emergency Treatment Of Type 1 Allergic Reactions In Children Weighing 15 Kg To Less Than 30 Kg	CI

Adarx Pharmaceuticals appoints industry veteran, Laura Shawver, Ph.D., as board chair

Published on 09/17/2025 at 09:20 am EDT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about ARS Pharmaceuticals, Inc.

Feb. 10	Ars Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on Neffy®? (Epinephrine Nasal Spray) At 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting	CI
Feb. 02	ARS Pharmaceuticals Announces EURneffy 1 Mg (Adrenaline Nasal Spray) Recommended For Approval In The EU For Emergency Treatment Of Type 1 Allergic Reactions In Children Weighing 15 Kg To Less Than 30 Kg	CI
Feb. 02	ARS Pharmaceuticals Secures EMA Backing to Expand EURneffy Nasal Spray for Children With Anaphylaxis	MT
Feb. 02	US FDA declines to approve Aquestive's oral drug for allergic reactions	RE
Dec. 29	ARS Pharmaceuticals Wins China Approval for First Community-Use Epinephrine for Allergic Reactions	MT
Dec. 29	ARS Pharmaceuticals, Inc. Announces Approval in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (Anaphylaxis)	CI
Nov. 17	ARS Pharmaceuticals Insider Sold Shares Worth $1,476,147, According to a Recent SEC Filing	MT
Nov. 10	ARS Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 10, 2025
Nov. 10	ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 10	ARS Pharmaceuticals Q3 Net Loss Widens, Revenue Rises	MT
Nov. 10	Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss	MT
Nov. 10	Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q3 Revenue $32.5M, vs. FactSet Est of $28.7M	MT
Nov. 10	ARS Pharmaceuticals' Q3 loss widens on higher costs	RE
Nov. 04	Ars Pharmaceuticals, Inc. Launches Get Neffy on for Patients with Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)	CI
25-10-08	ARS Pharmaceuticals Says European Patent Office Upholds Nasal Spray Epinephrine Patent	MT

Chart ARS Pharmaceuticals, Inc.

Duration

Period

SPRY: Dynamic Chart

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Employees

165

Sector

Biotechnology & Medical Research

More about the company